Frovatriptan has a longer half-life than almotriptan (25–26 h vs. 3–4 h), and has one of the greatest 5-HT1B binding receptor affinity among triptans and multiple pathways metabolism, which might explain why frovatriptan, unlike almotriptan, greatly reduced the risk of migraine recurrence [20]. This evidence concerns the gene HTR1B and migraine disorder.